111 related articles for article (PubMed ID: 15006843)
1. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6.
Bressler SB; Pieramici DJ; Koester JM; Bressler NM
Arch Ophthalmol; 2004 Mar; 122(3):325-9. PubMed ID: 15006843
[TBL] [Abstract][Full Text] [Related]
2. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
Pieramici DJ; Bressler SB; Koester JM; Bressler NM
Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587
[TBL] [Abstract][Full Text] [Related]
3. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
Bressler NM;
Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
Barbazetto I; Burdan A; Bressler NM; Bressler SB; Haynes L; Kapetanios AD; Lukas J; Olsen K; Potter M; Reaves A; Rosenfeld P; Schachat AP; Strong HA; Wenkstern A; ;
Arch Ophthalmol; 2003 Sep; 121(9):1253-68. PubMed ID: 12963608
[TBL] [Abstract][Full Text] [Related]
8. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
[TBL] [Abstract][Full Text] [Related]
9. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
Verteporfin In Photodynamic Therapy Study Group
Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
[TBL] [Abstract][Full Text] [Related]
10. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
Blumenkranz MS; Bressler NM; Bressler SB; Donati G; Fish GE; Haynes LA; Lewis H; Miller JW; Monés JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Schachat AP; Schmidt-Erfurth U; Sickenburg M; Singerman LJ; Slakter JS; Strong A; Vannier S;
Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
Kaiser PK;
Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
Verteporfin Roundtable Participants
Retina; 2005; 25(2):119-34. PubMed ID: 15689800
[TBL] [Abstract][Full Text] [Related]
13. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration.
Frennesson CI; Nilsson SE
Acta Ophthalmol Scand; 2004 Dec; 82(6):645-50. PubMed ID: 15606458
[TBL] [Abstract][Full Text] [Related]
14. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
[TBL] [Abstract][Full Text] [Related]
15. Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes.
Harding SP; Tomlin K; Reeves BC; Langham J; Walker J; Carpenter J; Grieve R; Patton WP; Muldrew KA; Peto T; Chakravarthy U;
Ophthalmology; 2009 Dec; 116(12):e1-8. PubMed ID: 19948275
[TBL] [Abstract][Full Text] [Related]
16. Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4.
Rubin GS; Bressler NM;
Retina; 2002 Oct; 22(5):536-44. PubMed ID: 12441717
[TBL] [Abstract][Full Text] [Related]
17. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration.
Michels S; Wachtlin J; Gamulescu MA; Heimann H; Prünte C; Inhoffen W; Krebs I; Schmidt-Erfurth U
Ophthalmology; 2005 Dec; 112(12):2070-5. PubMed ID: 16225928
[TBL] [Abstract][Full Text] [Related]
18. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
Azab M; Benchaboune M; Blinder KJ; Bressler NM; Bressler SB; Gragoudas ES; Fish GE; Hao Y; Haynes L; Lim JI; Menchini U; Miller JW; Mones J; Potter MJ; Reaves A; Rosenfeld PJ; Strong A; Su XY; Slakter JS; Schmidt-Erfurth U; Sorenson JA; ;
Retina; 2004 Feb; 24(1):1-12. PubMed ID: 15076937
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
Arias L; Garcia-Arumi J; Ramon JM; Badia M; Rubio M; Pujol O
Ophthalmology; 2006 Dec; 113(12):2243-50. PubMed ID: 16996600
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy with verteporfin in patients with age-related macular degeneration and juxtafoveal choroidal neovascularization.
Frennesson CI
Acta Ophthalmol Scand; 2004 Dec; 82(6):651-5. PubMed ID: 15606459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
